Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline. It has licensed ALXN-1840, a candidate for the treatment of Wilson disease that was previously ...
Monopar Therapeutics Inc. presented new data on its drug candidate ALXN1840 (tiomolybdate choline) for Wilson disease at the European Association for the Study of the Liver International Liver ...
Eton Pharmaceuticals has launched Galzin® (zinc acetate) capsules, the only FDA-approved zinc therapy for Wilson disease patients who have previously been treated with a chelating agent. To enhance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results